Genistein induces G2 arrest in malignant B cells by decreasing IL-10 secretion

Cell Cycle

Volumn 3, Issue 12, 2004, Pages 1597-1605

  Mansour, Amal ^a   McCarthy, Brian ^a   Schwander, Stephan K ^a   Chang, Victor ^a,b   Kolenko, Sergei ^a   Donepudi, Sreekrishna ^a   Lee, Janet ^a   Raveche, Elizabeth ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b VA New Jersey Health Core SYstem   (United States)

Author keywords

B cell malignancy; Fludarabine; Genistein; Ian5; IL 10; Survivin

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE 1; FLUDARABINE; GAMMA INTERFERON; GENISTEIN; INTERLEUKIN 10; ISOFLAVONE DERIVATIVE; PROTEIN; PROTEIN CDC25C; PROTEIN LAN 5; PROTEIN TYROSINE KINASE INHIBITOR; SURVIVIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; DRUG DERIVATIVE; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN RECEPTOR; MESSENGER RNA; VIDARABINE;

ARTICLE; BURKITT LYMPHOMA; CELL CYCLE; CELL CYCLE G2 PHASE; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFECT; DRUG WITHDRAWAL; GROWTH INHIBITION; HUMAN; HUMAN CELL; NONHODGKIN LYMPHOMA; NUCLEOTIDE SEQUENCE; PROLYMPHOCYTIC LEUKEMIA; SOYBEAN; UPREGULATION; APOPTOSIS; B LYMPHOCYTE; BIOSYNTHESIS; CELL CULTURE; CYTOTOXICITY; DOSE RESPONSE; FLOW CYTOMETRY; GENETICS; METABOLISM; PATHOLOGY; SECRETION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; B-LYMPHOCYTES; CELL CYCLE PROTEINS; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; G2 PHASE; GENISTEIN; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-10; RNA, MESSENGER; TUMOR CELLS, CULTURED; VIDARABINE;

EID: 17144409027     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.3.12.1293     Document Type: Article

References (69)

1. Casagrande F, Darbon J. Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: Regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol 2001; 61:1205-15.
2. Suzuki K, Koike H, Matsui H, Ono Y, Hasumi M, Nakazato H, Okugi H, Sekine Y, Oki K, Ito K, Yamamoto T, Fukabori Y, Kurokawa K, Yamanaka H. Genistein, a soy isoflavone, induces glutathione peroxidase in the human prostate cancer cell lines LNCaP and PC-3. Int J Cancer 2002; 99:846-52.
3. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987; 262:5592-5.
4. Fioravanti L, Cappelletti V, Miodini P, Ronchi E, Brivio M, Di Fronzo G. Genistein in the control of breast cancer cell growth: Insights into the mechanism of action in vitro. Cancer Lett 1998; 130:143-52.
5. Constantinou AI, Krygier AE, Mehta RR. Genistein induces maturation of cultured human breast cancer cells and prevents tumor growth in nude mice. Am J Clin Nutr 1998; 68:14265-305.
6. Li Y, Upadhyay S, Bhuiyan M, Sarkar FH. Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene 1999; 18:3166-72.
7. Traganos F, Ardelt B, Halko N, Bruno S, Darzynkiewicz Z. Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells. Cancer Research 1992; 52:6200-8.
8. Sarkar F, Li Y. Soy isoflavones and cancer prevention. Cancer Invest 2003; 21:744-57.
9. Allred CD, Allred KF, Ju YH, Virant SM, Helferich WG. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res 2001; 61:5045-50.
10. Record IR, Jannes M, Dreosti IE, King RA. Induction of micronucleus formation in mouse splenocytes by the soy isoflavone genistein in vitro but not in vivo. Food Chem Toxicol 1995; 33:919-22.
11. Krupp G, Kuhne K, Tamm S, Klapper W, Heidorn K, Rott A, Parwaresch R. Molecular basis of artifacts in the detection of telomerase activity and a modified primer for a more robust 'TRAP' assay. Nucleic Acids Research 1997; 25:919-21.
12. Uckun FM, Messinger Y, Chen CL, O'Neill K, Myers DE, Goldman F, Hurvitz C, Casper J T, Levine A. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. Clin Cancer Res 1999; 5:3906-13.
13. Chen CL, Levine A, Rao A, O'Neill K, Messinger Y, Myers DE, Goldman F, Hurvitz C, Casper JT, Uckun FM. Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in patients with B-lineage lymphoid malignancies. J Clin Pharmacol 1999; 39:1248-55.
14. Kumagai A, Dunphy WG. The cdc25 protein controls tyrosine dephosphorylation of the cdc2 protein in a cell-free system. Cell 1991; 64:903-14.
15. Karlsson C, Katich S, Hagting A, Hoffmann I, Pines J. Cdc25B and Cdc25C differ markedly in their properties as initiators of mitosis. J Cell Biol 1999; 146:573-84.
16. 2/M cell cycle transition. FEBS Lett 1999; 444:32-7.
17. kip1, and Cdc25C expression. Biochem Pharmacol 2001; 61:979-89.
18. 2 arrest caused by genistein in human melanoma cells. Exp Cell Res 2000; 258:101-8.
19. Alas S, Emmanouilides C, Bonavida B. Inhibition of IL-10 by Rituximab results in downregulation of bcl-2 and sensitization of B cell NHL to apoptosis. Clin Canc Res 2001; 7:709-23.
20. WAF1 in prostate cancer cells: Role in cell cycle, alteration of phenotype and invasive potential. Int J Cancer 1998; 77:138-45.
21. Ramachandra S, Metcalf RA, Fredrickson T, Marti GE, Raveche E. Requirement for increased IL-10 in the development of B-1 lymphoproliferative disease in a murine model of CLL. J Clin Invest 1996; 98:1788-93.
22. Chong S, Lin Y, Czarneski J, Zhang M, Coffman F, Kashanchi F, Raveché E. Cell cycle effects of IL-10 on malignant B-1 cells. Genes and Immunity 2001; 2:239-47.
23. 2-M cell cycle arrest. Oncol Rep 1998; 5:23-30.
24. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-nonHodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in downregulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001; 61:5137-44.
25. Verlengia R, Gorjao R, Kanunfre CC, Bordin S, de Lima TM, Newsholme P, Curi R. Genes regulated by arachidonic and oleic acids in Raji cells. Lipids 2003; 38:1157-65.
26. Mitamura K, Suenaga R, Wilson KB, Abdou NI. V gene sequences of human anti-ssDNA antibodies secreted by lupus-derived CD5-negative B cell hybridomas. Clin Immunol Immunopathol 1996; 78:152-60.
27. Melo J, Foroni L, Brito-Babapulle V, Luzzatto L, Catovsky D. The establishment of cell lines from chronic B cell leukaemias: Evidence of leukaemic origin by karyotypic abnormalities and Ig gene rearrangement. Clin Exp Immunol 1988; 73:23-8.
28. Nicoletti I, Migliorati G, Pagliacci M, Grignani F, Riccardi C. A rapid simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J of Immunol Meth 1991; 139:271-9.
29. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Meth 1983; 65:55.
30. + T cells via ELISPOT in PBMC: Cognate vs. nonspecific production of the cytokine. J Immunol Methods 2003; 279:111-2.
31. Gary-Gouy H, Harriague J, Bismuth G, Platzer C, Schmit C, Dalloul A. Human CD5 promotes B cell survival through stimulation of autocrine IL-10 production. Blood 2002; 100:4537-43.
32. Conti P, Kempuraj D, Kandere K, Di Gioacchino M, Barbacane RC, Castellani ML, Felaco M, Boucher W, Letourneau R, Theoharides TC. IL-10, an inflammatory/inhibitory cytokine, but not always. Immunol Lett 2003; 86:123-9.
33. Rao V, Plunkett W. Activation of a p53-mediated apoptotic pathway in quiescent lymphocytes after the inhibition of DNA repair by fludarabine. Clin Cancer Res 2003; 9:3204-12.
34. Yamauchi T, Nowak B, Keating M, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydropetoxycyclophosphamide is inhibited by fludatabine and clofarabine. Clin Cancer Res 2001; 7:3580-9.
35. Bertrand FE, Eckfeldt CE, Fink JR, Lysholm AS, Ptibyl JA, Shah N, LeBien TW. Microenvironmental influences on human B-cell development. Immunol Rev 2000; 175:175-86.
36. Lagneaux L, Delfotge A, De Bruyn C, Bernier M, Bron D. Adhesion to bone matrow stroma inhibits apoptosis of chronic lymphocytic leukemia cells. Leuk Lymphoma 1999; 35:445-53.
37. Bartik MM, Welket D, Kay NE. Impaitments in immune cell function in B cell chronic lymphocytic leukemia. Semin Oncol 1998; 25:27-33.
38. + T cells from B-CLL patients: Impact on clonal B-cell apoptosis. Br J Haematol 2001; 112:760-7.
39. Aydin F, Yilmaz M, Ozdemir F, Kavgaci H, Yavuz MN, Yavuz AA. Correlation of serum IL-2, IL-6 and IL-10 levels with International Prognostic Index in patients with aggressive nonHodgkin's lymphoma. AmJ Clin Oncol 2002; 25:570-2.
40. Lai R, Rassidakis GZ, Medeiros LJ, Leventaki V, Keating M, McDonnell TJ. Expression of STAT3 and its phosphorylated forms in mantle cell lymphoma cell lines and tumours. J Pathol 2003; 199:84-9.
41. Ohno T, Ueda Y, Nagai K, Takahashi T, Konaka Y, Takamatsu T, Suzuki T, Sasada M, Uchiyama T. The serum cytokine profiles of lymphoma-associated hemophagocytic syndrome: A comparative analysis of B-cell and T-cell/natural killet cell lymphomas. Int J Hematol 2003; 77:286-94.
42. Ke Y, Kapp LM, Kapp JA. Inhibition of tumor rejection by γΔ T cells and IL-10. Cell Immunol 2003; 221:107-14.
43. Bonig H, Korholz D, Pafferath B, Mauz-Korholz C, Burdach S. Interleukin 10 induced c-fos expression in human B cells by activation of divergent protein kinases. Immunol Invest 1996; 25:115-28.
44. waf1/cip1 and Weel. Biochem Pharmacol 2004; 67:717-26.
45. Powell M, Thompson S, Tone Y, Waldmann H, Tone M. Posttranscriptional regulation of IL-10 gene expression through sequences in the 3′-untranslated region. J Immunol 2000; 195:292-6.
46. Tone M, Powell M, Tone Y, Thompson S, Waldmann H. IL-10 gene expression is controlled by the transcription factors Sp1 and Sp3. J Immunol 2000; 165:286-91.
47. Haidweger E, Novy M, Rotheneder H. Modulation of Sp1 activity by a cyclin A/CDK complex. J Mol Biol 2001; 306:201-12.
48. Shou J, Soriano R, Hayward SW, Cunha GR, Williams PM, Gao WQ. Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Proc Natl Acad Sci USA 2002; 99:2830-5.
49. Geller J, Petak I, Szucs KS, Nagy K, Tillman DM, Houghton JA. Interferon-γ-induced sensitization of colon carcinomas to ZD9331 targets caspases, downstream of Fas, independent of mitochondrial signaling and the inhibitor of apoptosis survivin. Clin Cancer Res 2003; 9:6504-15.
50. Naraghi S, Khoshyomn S, DeMattia JA, Vane DW. Receptor tyrosine kinase inhibition suppresses growth of pediatric renal tumor cells in vitro. J Pediatr Surg 2000; 35:884-90.
51. Penar PL, Khoshyomn S, Bhushan A, Tritton TR. Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain. Neurosurgery 1997; 40:141-51.
52. Li H, Sun B, Feng Q, Shang Z. Expression of survivin and caspase-3 in nonHodgkin's lymphoma and their clinical significance. Ai Zheng 2004; 23:40-3.
53. Kuttler F, Valnet-Rabier MB, Angonin R, Ferrand C, Deconinck E, Mougin C, Cahn J Y, Fest T. Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: A preferential survivin-cyclin B link. Leukemia 2002; 16:726-35.
54. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, Dombret H, Reyes F, Diebold J, Gisselbrecht C, Salles G, Altieri D C, Molina T J. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96:1921-5.
55. Li F. Survivin study: What is the next wave? J Cell Physiol 2003; 197:8-29.
56. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003; 101:1535-42.
57. Gordan JD, Vonderheide RH. Universal tumor antigens as targets for immunotherapy. Cytotherapy 2002; 4:317-27.
58. Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW Effects of survivin antagonists on growth, of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 2001; 93:1541-52.
59. Schimmer AD, Munk-Pedersen I, Minden MD, Reed JC. Bcl-2 and apoptosis in chronic lymphocytic leukemia. Curr Treat Options Oncol 2003; 4:211-8.
60. Daheron L, Zenz T, Siracusa LD, Brenner C, Calabretta B. Molecular cloning of Ian4: A BCR/ABL-induced gene that encodes an outer membrane mitochondrial protein with GTP-binding activity. Nucleic Acids Res 2001; 29:1308-16.
61. Zenz T, Roessner A, Thomas A, Frohling S, Dohner H, Calabretta B, Daheron L. hIan5: The human ortholog to the rat Ian4/Iddm1/lyp is a new member of the Ian family that is overexpressed in B-cell lymphoid malignancies. Genes Immun 2004; 5:109-16.
62. Pandarputkar M, Wilson-Fritch L, Corveta S, Matkholst H, Hornum L, Greinet D, Mordes J, Rossini A, Bortell R. Ian4 is required for mitochondrial integrity and T cell survival. Proc Nad Acad Sci USA 2003; 100:10382-7.
63. Hochstet H, Cassileth P. Fludarabine phosphate therapy of nonHodgkin's lymphoma. Semin Oncol 1990; 17:63-5.
64. Densmore JJ, Williams ME. Mantle cell lymphoma. Curr Treat Options Oncol 2003; 4:281-7.
65. Bytd JC, Lucas DM, Mone AP, Kitner JB, Drabick JJ, Grever MR. KRN5500: A novel therapeutic agent with in vitro activity against human B-cell chtonic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis. Blood 2003; 101:4547-50.
66. Bryrd J, White C, Link B. Rituximab in Waldenstrom's macroglobulinemia. Ann Oncol 1999; 10:1526-7.
67. Mohammad R, Al-Katib A, Aboukameel A, Doerge D, Sarkar F, Kucuk O. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. Mol Cancer Ther 2003; 2:1361-8.
68. Nakagawa H, Yamamoto D, Kiyozuka Y, Tsuta K, Uemura Y, Hioki K, Tsutsui Y, Tsubura A. Effects of genistein and synergistic action in combination with eicosapentaenoic acid on the growth of breast cancer cell lines. J Cancer Res Clin Oncol 2000; 126:448-54.
69. Miltyk W, Craciunescu CN, Fischer L, Jeffcoat RA, Koch MA, Lopaczynski W, Mahoney C, Crowell J, Paglieri J, Zeisel SH. Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr 2003; 77:875-82.